检索结果-南通市图书馆

维普期刊数据库

在线全文

学校读者我要写书评

暂无评论

限界型血管角皮瘤:1例报道及文献回顾

世界核心医学期刊文摘（皮肤病学分册） 2006年第3期2卷 60-60页

作者： mittal R. Aggarwal A. Srivastava G. 罗素菊 Skin Institute and School of Dermatology N block Greater Kailash-1 New Delhi-110 048 India Dr

The term “ angiokeratoma” is applied to several distinct conditions with vascular skin lesions, the histology of which shows superficial vascular ectasia and overlying hyperkeratosis. The angiokeratomas should be regarded as capillary vascular malformation rather than hemangiomas. Apart from angiokeratoma corporis diffusum (Fabry), which is a disorder of phospholipid metabolism, at least four types of purely cutaneous angiokeratoma are known: the Mibelli type, the Fordyce type, angiokeratoma circumscriptumand “ solitary and multiple angiokeratoma” (imperial and Helwig). We present here a case of angiokeratoma circumscriptum and a brief review of the literature.

关键词：躯体血管角皮瘤文献回顾组织学改变浅表血管扩张毛细血管畸形不同疾病血管瘤弥漫性代谢病单纯性

维普期刊数据库

诊断性治疗试验的意义:皮肤结核对治疗产生反应需要多久?

在线全文

学校读者我要写书评

暂无评论

世界核心医学期刊文摘（皮肤病学分册） 2005年第6期1卷 55-55页

作者： Ramam M. mittal R. Ramesh V. 张宪旗 Dr.Dept. of Dermatology and Venereology All India Inst. of Medical SciencesNewDelhi110029India

Background: It is difficult to demonstrate Mycobacterium tuberculosis in smears or biopsies and to grow it in culture in cutaneous tuberculosis because most cases are paucibacillary. A therapeutic trial of antitubercular drugs is frequently used to confirm the diagnosis in difficult cases. Information is lacking on the response to antitubercular therapy in cutaneous tuberculosis; consequently there are no clear guidelines on when to expect a response and also when to abandon a therapeutic trial. Methods: We studied the records of 60 patients treated for cutaneous tuberculosis at our hospital to study the time course of the therapeutic response. All patients were treated with a short-course antitubercular regimen consisting of isoniazid 300 mg daily, rifampicin 450 mg daily, ethambutol 800 mg daily and pyrazinamide 1500 mg daily for 2 months followed by isoniazid and rifampicin in the same doses for 4 months. At follow-up visits, each patient was assessed by a dermatologist who recorded the presence or absence of clinical improvement in the skin lesions. Results: Of the 60 patients seen, eight patients did not follow up after the initial consultation, 48 patients improved with treatment and four patients were classified as treatment failures. The timing of the first visit varied from 3 days to 15 months (median 27.5 days, mean 58.96 ± .94.50) after initiation of treatment. Twenty-one patients were recorded to have improved within the first month of therapy. Twenty- seven patients who first reported more than 30 days after initiation of treatment were found to have improved. Four patients failed to respond during follow up ranging from 3 to 17 months. Conclusion: When a therapeutic trial is undertaken in cutaneous tuberculosis,6 weeks of therapy with four drugs appears adequate to prove (or disprove) the diagnosis.

关键词：皮肤结核抗结核药物临床改善吡嗪疑难病例皮肤科医师失访周足

维普期刊数据库

Association of latitude and altitude with adverse outcomes in patients with COVID-19: The VIRUS registry

在线全文

学校读者我要写书评

暂无评论

World Journal of Critical Care Medicine 2022年第2期11卷 102-111页

作者： Aysun Tekin Shahraz Qamar Romil Singh Vikas Bansal mayank Sharma Allison M LeMahieu Andrew C Hanson Phillip J Schulte Marija Bogojevic Neha Deo Simon Zec Diana J Valencia Morales Katherine A Belden Smith F Heavner Margit Kaufman Sreekanth Cheruku Valerie C Danesh Valerie M Banner-Goodspeed Catherine A St Hill Amy B Christie Syed A Khan Lynn Retford Karen Boman Vishakha KKumar John C O'Horo Juan Pablo Domecq Allan J Walkey Ognjen Gajic Rahul Kashyap Salim Surani TheSociety of Critical Care Medicine(SCCM)Discovery Viral Infection and Respiratory Illness Universal Study(VIRUS):COVID-Registry Investigator Group Department of Anesthesiology Mayo ClinicRochesterMN 55905United States Post-baccalaureate Research Education Program Mayo Clinic College of Medicine and ScienceRochesterMN 55905United States Division of Pulmonary and Critical Care Medicine Department of Internal MedicineMayo ClinicRochesterMN 55905United States Division of Clinical Trials and Biostatistics Department of Quantitative Health SciencesMayo ClinicRochesterMN 55905United States Alix School of Medicine Mayo ClinicRochesterMN 55905United States Division of Infectious Diseases Thomas Jefferson University HospitalPhiladelphiaPA 19107United States Prisma Health GreenvilleSC 29605United States Englewood Health EnglewoodNJ 07631United States Divisions of Cardiothoracic Anesthesiology and Critical Care Medicine Department of Anesthesiology and Pain ManagementUT Southwestern Medical CenterDallasTX 75390United States Center for Applied Health Research Baylor Scott and White HealthDallasTX 75246United States Department of Anesthesiology Critical Care and Pain MedicineBeth Israel Deaconess Medical CenterBostonMA 02215United States Allina Health MinneapolisMN 55407United States Department of Critical Care Atrium Health NavicentMaconGA 31201United States Division of Critical Care Medicine Mayo Clinic Health SystemMankatoMN 56001United States Society of Critical Care Medicine Mount ProspectIL 60056United States Division of Infectious Diseases Mayo ClinicRochesterMN 55905United States Division of Nephrology and Hypertension Department of Internal MedicineMayo ClinicRochesterMN 55905United States Pulmonary Center Division of PulmonaryAllergyCritical Care and Sleep MedicineDepartment of MedicineEvans Center of Implementation and Improvement SciencesBoston University School of MedicineBostonMA 02118United States Department of Pulmonary and Critical Care Medicine Texas A&M UniversityBryanTX 77807United States 不详

BACKGROUND The coronavirus disease 2019(COVID-19)course may be affected by environmental *** studies previously suggested a link between climatological factors and COVID-19 fatality ***,individual-level impact of these factors has not been thoroughly evaluated *** To study the association of climatological factors related to patient location with unfavorable outcomes in *** In this observational analysis of the Society of Critical Care Medicine Discovery Viral Infection and Respiratory Illness Universal Study:COVID-19 Registry cohort,the latitudes and altitudes of hospitals were examined as a covariate for mortality within 28 d of admission and the length of hospital *** for baseline parameters and admission date,multivariable regression modeling was *** estimating equations were used to fit the *** Twenty-two thousand one hundred eight patients from over 20 countries were *** median age was 62(interquartile range:49-74)years,and 54%of the included patients were *** median age increased with increasing latitude as well as the frequency of ***,the percentage of comorbidities was lower in elevated *** within 28 d of hospital admission was found to be 25%.The median hospital-free days among all included patients was 20 *** the significant linear relationship between mortality and hospital-free days(adjusted odds ratio(aOR)=1.39(1.04,1.86),P=0.025 for mortality within 28 d of admission;aOR=-1.47(-2.60,-0.33),P=0.011 for hospital-free days),suggesting that adverse patient outcomes were more common in locations further away from the Equator;the results were no longer significant when adjusted for baseline differences(aOR=1.32(1.00,1.74),P=0.051 for 28-day mortality;aOR=-1.07(-2.13,-0.01),P=0.050 for hospital-free days).When we looked at the altitude’s effect,we discovered that it demonstrated a non-linear association with mortality wi

关键词： 28 d mortality Altitude COVID-19 Hospital-free days Latitude Outcomes

12周的来迪派韦/索磷布韦用于3至<6岁的慢性丙型肝炎病毒儿童感染患者时安全有效

维普期刊数据库评论

在线全文

维普期刊数据库

学校读者我要写书评

暂无评论

12周的来迪派韦/索磷布韦用于3至<6岁的慢性丙型肝炎病毒儿童感染...

心电门控CT冠状动脉成像对同种异体移植心脏血管病变的评估

第十届全国疑难及重症肝病大会

作者： Kathleen B.Schwarz Philip Rosenthal Karen F.Murray Jonathan Robert Honegger Winita Hardikar Rosemary Hague Naveen mittal Benedetta Massetto Diana Brainard Rebecca Begley Bandita Parhy Jiang Shao Michael R.Narkewicz Girish S.Rao Suzanne Whitworth Sanjay Bansal William F.Balistreri Johns Hopkins Hospital University of California San Francisco University of Washington School of Medicine and Seattle Children's Hospital The Ohio State University Medical Center The Royal Children's Hospital

背景基于索磷布韦的治疗方案已被批准用于12至<18岁的青少年患者,但对于年龄更小的儿童患者而言,标准治疗方案仍然是长达48周的聚乙二醇化干扰素+利巴韦林。之前,我们报告了有关12周或24周的来迪派韦/索磷布韦固定剂量组合(LDV/SOF FDC...

背景基于索磷布韦的治疗方案已被批准用于12至<18岁的青少年患者,但对于年龄更小的儿童患者而言,标准治疗方案仍然是长达48周的聚乙二醇化干扰素+利巴韦林。之前,我们报告了有关12周或24周的来迪派韦/索磷布韦固定剂量组合(LDV/SOF FDC)用于6至<12岁的患者中时的数据,其SVR12率分别为99%-100%。本研究评估了全口服LDV/SOF FDC疗法用于3至<6岁

关键词：

来源： cnki会议评论

在线全文

cnki会议

学校读者我要写书评

暂无评论

国际医学放射学杂志 2013年第5期 479-479页

作者： T.K.mittal M.G.Panicker A.G.Mitchell N.R.Banner 常丹丹 Department of Imaging Harefield HospitalRoyal Brompton & Harefield NHS Foundation Trust

摘要目的与有创性血管造影比较,评价不应用β受体阻滞剂的CT血管成像诊断同种异体移植心脏的血管病变(cardiac allograft vasculopathy,CAV)的准确性。方法本研究经伦理委员会同意,所有参与者均签署知情同意书。本前瞻性研究纳入拟行有... 详细信息

摘要目的与有创性血管造影比较,评价不应用β受体阻滞剂的CT血管成像诊断同种异体移植心脏的血管病变(cardiac allograft vasculopathy,CAV)的准确性。方法本研究经伦理委员会同意,所有参与者均签署知情同意书。本前瞻性研究纳入拟行有创性血管造影检查的心脏移植受者138例。行64层螺旋CT平扫评估冠状动脉钙化,并行心电门控CT冠状动脉成像。系统分析CT血管成像影像质量,采用冠状动脉15节段模型评估CAV程度。分别计算心脏CT血管成像检出CAV合并冠状动脉任意程度狭窄和CAV合并冠状动脉50%或以上狭窄的敏感度、特异度、阳性预测值、

关键词：冠状动脉成像同种异体移植同种(异体)移植心电门控血管病变心脏 CT